Evidence map›Paper›PMID 30915644›Full record

ReviewIndian journal of pediatrics2019

Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Aparna Mukherjee, Rakesh Lodha, S K Kabra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Indian journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Advances in Tuberculosis: Diagnostics.Indian journal of pediatrics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aparna MukherjeeDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Rakesh LodhaDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India. rakesh_lodha@hotmail.com.
S K KabraDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining the optimal dosages of isoniazid, rifampicin, pyrazinamide and ethambutol in children is necessary to obtain therapeutic serum concentrations of these drugs. Revised dosages have improved the exposure of 1st line anti-tubercular drugs to some extent; there is still scope for modification of the dosages to achieve exposures which can lead to favourable outcome of the disease. High dose of rifampicin is being investigated in clinical trials in adults with some benefit; studies are required in children. Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual.

Indexed as

Age FactorsAntitubercular AgentsChildDrug OverdoseEthambutolFoodGenotypeHIV InfectionsHumansIsoniazidMalnutritionNutritional StatusPolymorphism, GeneticPyrazinamideRifampinTreatment OutcomeAntitubercular AgentsEthambutolIsoniazidPyrazinamideRifampinAnti tuberculosis drugsEthambutolIsoniazidPyrazinamideRifampicin

Identifiers

PMID30915644
OpenAlexW2923456140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.